Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by narmacon Mar 31, 2022 9:37am
179 Views
Post# 34562499

Last trading day in 1stQ of 2022!

Last trading day in 1stQ of 2022!sooo,,the first quarter of 2022 slips past us today as we struggle to advance our science. XB3-001 remains sidelined with no partner identified as of this time to shareholders.I am not a biotech business admin person but with the huge number of drugs in wait for a method to cross the BBB we should pass over our 001 program as a charitable donation to humanity! Allow a Pharma who has interest to take our science into the clinic and demonstrate its ability or inability to perform as our team describes. This would set up two very important postions for BTI...it would show the humanitarian aspect around the compnays' position in developing life saving technology and it would be undilutive to shareholders! The science needs clinical proof and what an honorable way to achieve it. Does the company and  sharholders need to spearhead all our programs?...I think not,,,,,we are not  a one trick pony so we should be using this very situation to everyones advantage imo, especially for those who need life saving treatments. We assume BTI needs more data to trigger greater interest froim Pharma. I dont see any reason for us not to know when data has been completed. Data release is a different story of course!,,,,Pharma is said to be in wait for our data. But no info is avaialbale beyond the understanding that we are still in wait mode.   
<< Previous
Bullboard Posts
Next >>